0000000000417115

AUTHOR

Gabriella Casazza

showing 3 related works from this author

Autoimmune neutropenia of infancy: Data from the Italian neutropenia registry

2015

Pediatricsmedicine.medical_specialtybusiness.industryAutoimmune neutropeniamedicineMEDLINEHematologyNeutropeniamedicine.diseasebusinessAmerican Journal of Hematology
researchProduct

Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell su…

2008

Background We evaluated an intensified chemotherapy strategy in children with Wilms tumor who relapsed with high-risk features. Procedures From January 2001 to June 2006, we treated 20 consecutive children with reinduction chemotherapy (using ifosfamide/carboplatin/etoposide in 15/20 cases), with (n = 15) or without (n = 5) subsequent high-dose chemotherapy and hematopoietic stem cell support, surgery where feasible, and radiation therapy. The median time to relapse was 10 months after nephrectomy. All but two children initially received doxorubicin as first-line therapy. Results All patients were assessed for outcome: 13 are currently alive, 12 of them in remission a median 25 months since…

OncologyMaleTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationNephrectomyPediatricschemistry.chemical_compoundHigh-dose chemotherapyRelapseChildIfosfamideGraft SurvivalRemission InductionHematopoietic Stem Cell TransplantationHematologyPerinatology and Child HealthSurvival RateTreatment OutcomeItalyOncologyChild PreschoolAbsolute neutrophil countFemaleAutologousmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsTransplantation AutologousWilms TumorInternal medicinemedicineHumansPreschoolSurvival rateSalvage TherapyChemotherapyTransplantationbusiness.industryInfantWilms' tumormedicine.diseaseCarboplatinSurgeryRadiation therapychemistryPediatrics Perinatology and Child HealthAutologous hematopoietic stem cell transplantation; High-dose chemotherapy; Relapse; Wilms tumor; Antineoplastic Agents; Child; Child Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Italy; Male; Nephrectomy; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation Autologous; Treatment Outcome; Wilms Tumor; Pediatrics Perinatology and Child Health; Hematology; OncologybusinessAutologous hematopoietic stem cell transplantation
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct